"Glucagon-Like Peptide 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.
| Descriptor ID |
D052216
|
| MeSH Number(s) |
D06.472.317.469.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptide 1".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptide 1".
This graph shows the total number of publications written about "Glucagon-Like Peptide 1" by people in this website by year, and whether "Glucagon-Like Peptide 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 11 | 8 | 19 |
| 2018 | 6 | 11 | 17 |
| 2019 | 1 | 5 | 6 |
| 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Glucagon-Like Peptide 1" by people in Profiles.
-
Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity? Biochem Pharmacol. 2021 06; 188:114517.
-
Are glucagon-like peptide 1 analogues effective and safe in severe COVID-19 patients with type 2 diabetes?-a case report. Ann Palliat Med. 2021 Jun; 10(6):7057-7061.
-
Stabilizing Cellular Barriers: Raising the Shields Against COVID-19. Front Endocrinol (Lausanne). 2020; 11:583006.
-
Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review. BMJ Open. 2020 09 14; 10(9):e040644.
-
Response to COVID-19 and diabetes: Can DPP4 inhibition play a role? - GLP-1 might play one too. Diabetes Res Clin Pract. 2020 06; 164:108160.
-
Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity. J Clin Endocrinol Metab. 2019 11 01; 104(11):5703-5714.
-
Oleuropein-enriched chocolate by extra virgin olive oil blunts hyperglycaemia in diabetic patients: Results from a one-time 2-hour post-prandial cross over study. Clin Nutr. 2020 07; 39(7):2187-2191.
-
Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity. Life Sci. 2019 Oct 01; 234:116776.
-
Effects of novel antidiabetes agents on apoptotic processes in diabetes and malignancy: Implications for lowering tissue damage. Life Sci. 2019 Aug 15; 231:116538.
-
Anti-diabetic treatment leads to changes in gut microbiome. Front Biosci (Landmark Ed). 2019 03 01; 24(4):688-699.